Read More Pharma Industry News Why ESR1 mutation targeting is critical in metastatic breast cancer treatment FDA approves VEPPANU. Discover why ESR1 mutation targeting is reshaping metastatic breast cancer treatment and what it means next. bySoujanya RaviMay 4, 2026